Clinical Trials Browser

Phase 2 × Interventional × BMS-833923 × Clear all

NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2 Terminated

70 enrolled 8 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia